Radiation therapy used most often for prostate cancer regardless of decision-making factors
the ONA take:
The most common treatment for prostate cancer is radiation therapy, regardless of cancer stage, prostate-specific antigen (PSA) level, and prognosis and risk rating.
In an analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare linked data for 37,621 men with a prostate cancer diagnosis from 2004 to 2007, the researchers found radiation therapy was the most common treatment, followed by radical prostatectomy and other treatments including watchful waiting or active surveillance (WW-AS).
Radiation treatment was the most common regardless of stage, PSA level, and prognosis and tumor rating; however, PSA level influenced the choice of radical prostatectomy.
Clinical stage, as well as prognosis and tumor rating, influenced patients to choose WW-AS, but cancer stage, PSA level, and prognosis and risk rating prompted a decision to undergo androgen-deprivation therapy (ADT).
The authors reported that increased use of treatments in men with prostate cancer and underuse of active surveillance in men with low-risk disease remain.
Their study concludes that further research into what drives treatment choices among both patients and their physicians are needed.
Most common treatment for prostate cancer is radiation therapy, regardless of cancer stage.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
- Survey Reveals Research Priorities for Cancer Patients, Oncology Nurses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|